2.055USD-4.86%Mkt Cap: 912.82M USDP/E: —Last update: 2026-05-26
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, …
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap912.82M USD
Enterprise Value771.56M USD
Revenue (TTM)69.64M USD
Gross Profit49.53M USD
Net Income (TTM)-50.34M USD
Revenue/Share0.1870 USD
Last Price2.055 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees81
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.81
PEG-13.77
EV/EBITDA-32.66
EV/Revenue11.08
P/S14.22
P/B7.53
EPS (TTM)-0.07
EPS (Forward)-0.21
52W Range
0.620075% of range2.530
52W High2.530 USD
52W Low0.6200 USD
Profitability
Gross Margin99.45%
Oper. Margin-4.72%
EBITDA Margin-33.93%
Profit Margin-101.08%
ROE-46.81%
ROA-27.21%
Growth
Revenue Growth1572.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-67.85M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-120.97M USD
Net Debt/EBITDA5.12
Balance Sheet
Debt/Equity0.58
Current Ratio—
Quick Ratio—
Book Value/Sh0.2960 USD
Cash/Share0.4260 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:7
Split DateMay 21, 2015
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)3.720 USD
Target Range1.500 USD – 6.000 USD
# Analysts5
Ownership
Shares Out.444.20M
Float394.68M
Insiders0.98%
Institutions78.71%
Short Interest
Short Ratio12.2d
Short % Float10.14%
Short % Out.5.37%
Shares Short23.86M
Short (prev mo.)22.93M
Technical
SMA 501.786 (+15.0%)
SMA 2001.442 (+42.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)2.68M
Avg Vol (10d)4.25M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—